Please login to the form below
Crisaborole
This page shows the latest Crisaborole news and features for those working in and with pharma, biotech and healthcare.
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.
Latest news
-
Incyte’s JAK inhibitor cream clears second eczema trial
Its closest rival is likely to be Pfizer’s PDE-4 inhibitor Eucrisa (crisaborole) ointment, which was approved in the US in 2016, and generic corticosteroid creams that cause side effects
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
dupilumab) for moderate-to-severe symptoms and Pfizer’s Eucrisa (crisaborole) for milder forms.
-
Dermira craters as acne drug fails late-stage test
s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is
-
Roche out-licenses lebrikizumab rights to Dermira
Meanwhile, Pfizer is starting to make headway with its new topical treatment Eucrisa (crisaborole), which pulled in $17m in the first half of the year after its approval last December.
-
Regeneron bags US approval for eczema drug Dupixent
Dupixent's approval comes just a few weeks after Pfizer won a green light from the regulator for Eucrisa (crisaborole) for patients with milder forms of atopic dermatitis - which the company
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
Crisaborole is currently under FDA review. Late stage deals are not, however, a complete panacea. ... Corporate acquisition. Acquisition for $99.25 per share [55% premium], includes crisaborole under FDA review for mild to moderate eczema; est peak sales
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Wiley
Wiley is a global leader in research and education. We clear the path for seekers of knowledge, leading the way...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
